News
On September 3rd, Abbvie announced that epcoritamab has been included in the priority review list of the National Medical Products Administration's Drug Evaluation Center. This drug is used to treat adult patients with relapsed or refractory follicular lymphoma (FL)
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments